Cargando…

Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist

Due to the absence of curative treatments for glioblastoma (GBM), we assessed the efficacy of single and combination treatments with a translationally relevant 2nd generation TRAIL-receptor agonist (IZI1551) and the blood–brain barrier (BBB) permeant proteasome inhibitor marizomib in a panel of pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boccellato, Chiara, Kolbe, Emily, Peters, Nathalie, Juric, Viktorija, Fullstone, Gavin, Verreault, Maïté, Idbaih, Ahmed, Lamfers, Martine L. M., Murphy, Brona M., Rehm, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225658/ https://www.ncbi.nlm.nih.gov/pubmed/34168123 http://dx.doi.org/10.1038/s41419-021-03927-x

Ejemplares similares

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation
por: Juric, Viktorija, et al.
Publicado: (2021)

Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism
por: Lincoln, Frank A., et al.
Publicado: (2018)

Transcriptional CDK Inhibitors CYC065 and THZ1 Induce Apoptosis in Glioma Stem Cells Derived from Recurrent GBM
por: Juric, Viktorija, et al.
Publicado: (2021)

Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics
por: Lasri, Ayoub, et al.
Publicado: (2020)

Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
por: Krishna Moorthy, Nivetha, et al.
Publicado: (2021)

Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide
por: Weyhenmeyer, Birgit C., et al.
Publicado: (2016)

Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions
por: Juric, Viktorija, et al.
Publicado: (2020)

Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas
por: Jane, Esther P., et al.
Publicado: (2023)

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo
por: Manton, Christa A., et al.
Publicado: (2016)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism
por: Vetma, Vesna, et al.
Publicado: (2020)

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
por: Raninga, Prahlad V., et al.
Publicado: (2020)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

The FLAME-accelerated signalling tool (FaST) for facile parallelisation of flexible agent-based models of cell signalling
por: Fullstone, Gavin, et al.
Publicado: (2020)

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
por: Bota, Daniela A, et al.
Publicado: (2021)

Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids
por: Stöhr, Daniela, et al.
Publicado: (2020)

Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo
por: Zhang, Ziruizhuo, et al.
Publicado: (2022)

Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
por: Potts, Barbara C., et al.
Publicado: (2010)

Glioblastoma, from disease understanding towards optimal cell-based in vitro models
por: Boccellato, Chiara, et al.
Publicado: (2022)

Latest updates on cellular and molecular biomarkers of gliomas
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

The apoptosome molecular timer synergises with XIAP to suppress apoptosis execution and contributes to prognosticating survival in colorectal cancer
por: Fullstone, Gavin, et al.
Publicado: (2020)

Heterogeneity of Response to Iron-Based Metallodrugs in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes
por: Vessières, Anne, et al.
Publicado: (2021)

Possible Novel Therapy for Malignant Gliomas with Secretable Trimeric TRAIL
por: Jeong, Moonsup, et al.
Publicado: (2009)

Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights
por: Malaca, Sara, et al.
Publicado: (2021)

Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts
por: Liu, Y, et al.
Publicado: (2011)

Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks
por: Ganau, L., et al.
Publicado: (2015)

Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
por: Wajant, Harald
Publicado: (2019)

Modelling the Transport of Nanoparticles under Blood Flow using an Agent-based Approach
por: Fullstone, Gavin, et al.
Publicado: (2015)

Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma
por: Noonan, Janis J., et al.
Publicado: (2019)

Antitumor Activity of TRAIL Recombinant Adenovirus in Human Malignant Glioma Cells
por: Kim, Ki-Uk, et al.
Publicado: (2005)

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
por: Veneziani, Irene, et al.
Publicado: (2022)

TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
por: Tamada, Taro, et al.
Publicado: (2015)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells
por: Fabro, Federica, et al.
Publicado: (2023)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2009)

Pro-apoptotic effect of TRAIL-transfected endothelial progenitor cells on glioma cells
por: Deng, Xin, et al.
Publicado: (2018)

Grassroots Campaign Trail Methods to Recruit for Clinical Trials: Recruitment Lessons Learned from Trail to Trial
por: Murphy, Megan, et al.
Publicado: (2011)

Theranostic Design of Angiopep-2 Conjugated Hyaluronic Acid Nanoparticles (Thera-ANG-cHANPs) for Dual Targeting and Boosted Imaging of Glioma Cells
por: Costagliola di Polidoro, Angela, et al.
Publicado: (2021)

A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents
por: Arizono, Y, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_ukivv5ttv5np21s58nu6tv263u